Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paolo Alimonti, M.D.

Concepts (14)

Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Paolo Alimonti's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Paolo Alimonti has written about over time.
Animals, 1 publications between 2023 and 2023, average publication date November 2023. Disease Models, Animal, 1 publications between 2023 and 2023, average publication date November 2023. Mice, 1 publications between 2023 and 2023, average publication date November 2023. Glioblastoma, 2 publications between 2023 and 2024, average publication date January 2024. Astrocytes, 1 publications between 2024 and 2024, average publication date February 2024. Neoplasm Invasiveness, 1 publications between 2024 and 2024, average publication date February 2024. Brain Neoplasms, 3 publications between 2023 and 2024, average publication date March 2024. Humans, 3 publications between 2023 and 2024, average publication date March 2024. Glioma, 2 publications between 2024 and 2024, average publication date May 2024. Tumor Microenvironment, 2 publications between 2024 and 2024, average publication date May 2024. Child, 1 publications between 2024 and 2024, average publication date August 2024. Epigenesis, Genetic, 1 publications between 2024 and 2024, average publication date August 2024. Histones, 1 publications between 2024 and 2024, average publication date August 2024. Mutation, 1 publications between 2024 and 2024, average publication date August 2024.

To see the data from this visualization as text, click here.
Alimonti's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (14)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.